2024 Diagnostics Research Review

Table 1: Global Market for AI in Clinical and Molecular Diagnostics, by Type, Through 2029
Table 2: Global Market for AI in Clinical and Molecular Diagnostics, by Region, Through 2029
Table 3: Regulations Pertaining to AI Medical Diagnostics
Table 4: Global Market for AI in Clinical and Molecular Diagnostics, Through 2029
Table 5: Global Market for AI in Clinical and Molecular Diagnostics, by Type, Through 2029
Table 6: Global Market for AI in Molecular Diagnostics, by Application, Through 2029
Table 7: Incidence of Cancer, by Region, 2022
Table 8: Number of DALYs for Neurological Disorders and Share of Global DALYs Projected for 2005 and 2030
Table 9: Global Market for AI in Molecular Diagnostics, by Product Type, Through 2029
Table 10: Global Market for AI in Clinical Diagnostics, by Test, Through 2029
Table 11: Global Market for AI in Clinical Diagnostics, by Product, Through 2029
Table 12: Global Market for AI in Clinical and Molecular Diagnostics, by Component, Through 2029
Table 13: Global Market for AI in Clinical and Molecular Diagnostics, by Region, Through 2029
Table 14: North American Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
Table 15: European Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
Table 16: Asia-Pacific Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
Table 17: RoW Market for AI in Clinical and Molecular Diagnostics, by Sub-Region, Through 2029
Table 18: Global Market for Companion Diagnostics, by Product, Through 2028
Table 19: Global Market for Companion Diagnostics, by Region, Through 2028
Table 20: Expanded/New CDx Testing for Personalized Medicine in 2022
Table 21: Global Market for Companion Diagnostics, by Product and Service, Through 2028
Table 22: Companion Diagnostics Instruments
Table 23: Global Market for Companion Diagnostics Instruments, by Region, Through 2028
Table 24: Global Market for Companion Diagnostics Consumables, by Region, Through 2028
Table 25: Global Market for Companion Diagnostics Services, by Region, Through 2028
Table 26: Global Market for Companion Diagnostics, by Type of Test, Through 2028
Table 27: Global Market for Laboratory Developed Test (LDT)-CDx, by Region, Through 2028
Table 28: List of FDA-Approved Companion Diagnostics, by Company, as of December 2023
Table 29: Global Market for Commercial-CDx, by Region, Through 2028
Table 30: FDA-Approved CDx Tests, by Technology, as of December 2023
Table 31: Global Market for Companion Diagnostics, by Technology, Through 2028
Table 32: List of FDA-Approved PCR-CDx, by Company, as of December 2023
Table 33: Global Market for Polymerase Chain Reaction CDx, by Region, Through 2028
Table 34: Global Market for Polymerase Chain Reaction CDx, by Application, Through 2028
Table 35: List of FDA-Approved IHC-CDx, by Company, as of December 2023
Table 36: Global Market for Immunohistochemistry CDx, by Region, Through 2028
Table 37: Global Market for Immunohistochemistry CDx, by Application, Through 2028
Table 38: List of FDA-Approved NGS-CDx, by Company, as of December 2023
Table 39: Global Market for Next-Generation Sequencing CDx, by Region, Through 2028
Table 40: Global Market for Next-Generation Sequencing CDx, by Application, Through 2028
Table 41: Global Market for In Situ Hybridization CDx, by Region, Through 2028
Table 42: Global Market for In Situ Hybridization CDx, by Application, Through 2028
Table 43: Global Market for Genotyping CDx, by Region, Through 2028
Table 44: Global Market for Genotyping CDx, by Application, Through 2028
Table 45: Global Market for Immunoassays CDx, by Region, Through 2028
Table 46: Global Market for Immunoassays CDx, by Application, Through 2028
Table 47: Global Market for Exosome CDx, by Region, Through 2028
Table 48: Global Market for Exosomes CDx, by Application, Through 2028
Table 49: Global Market for Other CDx, by Region, Through 2028
Table 50: Global Market for Other CDx, by Application, Through 2028
Table 51: Technological Expertise in the CDx Services Sector
Table 52: Global Market for CDx Services, by Region, Through 2028
Table 53: Global Market for CDx Services, by Application, Through 2028
Table 54: Global Market for Companion Diagnostics, by Application, Through 2028
Table 55: Global Market for Companion Diagnostics in Cancer Applications, by Region, Through 2028
Table 56: Cancer Incidence, Global, by Cancer Type, 2022
Table 57: Approved CDx Drugs for Cancer Treatment, by Cancer Type, 2023
Table 58: Global Market for Companion Diagnostics in Cancer Applications, by Cancer Type, Through 2028
Table 59: Global Market for Companion Diagnostics in Neurologic Disorder Applications, by Region, Through 2028
Table 60: Global Market for Companion Diagnostics in Neurologic Disorder Applications, by Type, Through 2028
Table 61: Global Market for Companion Diagnostics in Cardiovascular Disease Applications, by Region, Through 2028
Table 62: Global Market for Companion Diagnostics in Infectious Disease Applications, by Region, Through 2028
Table 63: Global Market for Companion Diagnostics in Other Disease Applications, by Region, Through 2028
Table 64: Global Market for Companion Diagnostics, by End User, Through 2028
Table 65: Global Market for Companion Diagnostics in Clinical Laboratories, by Region, Through 2028
Table 66: Recent Collaborations and Partnerships in the Companion Diagnostics Market, 2022 and 2023
Table 67: Global Market for Companion Diagnostics in Pharmaceutical Companies, by Region, Through 2028
Table 68: Global Market for Companion Diagnostics in Contract Research Organizations, by Region, Through 2028
Table 69: Global Market for Companion Diagnostics in Other End Users, by Region, Through 2028
Table 70: Global Market for Companion Diagnostics, by Region, Through 2028
Table 71: North American Market for Companion Diagnostics, by Country, Through 2028
Table 72: European Market for Companion Diagnostics, by Country, Through 2028
Table 73: Asia-Pacific Market for Companion Diagnostics, by Country, Through 2028
Table 74: Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
Table 75: Blood-Related Disorders
Table 76: Incidence of Blood Cancer Types in U.S., 2023
Table 77: Total Cost of Care for CLL Patients Treated in the U.S., 2023
Table 78: Global Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 79: Global Market for Diagnostics for Hematological Disorders, by Region, Through 2029
Table 80: Global Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 81: Global Market for Hematology Instruments and Software, by Region, Through 2029
Table 82: Global Market for Hematology Reagents, by Region, Through 2029
Table 83: Global Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 84: Global Market for Hematology Diagnosis in Diagnostic Centers, by Region, Through 2029
Table 85: Global Market for Hematology Diagnosis in Hospitals and Clinics, by Region, Through 2029
Table 86: Global Market for Hematology Diagnosis in Other End Users, by Region, Through 2029
Table 87: Global Market for Hematology Drugs, by Region, Through 2029
Table 88: Global Market for Hematology Drugs, by Drug Type, Through 2029
Table 89: Drugs Approved for Hematologic Cancers
Table 90: Global Market for Hematology Oncology Drugs, by Region, Through 2029
Table 91: Global Market for Hematology Non-Oncology Drugs, by Region, Through 2029
Table 92: Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
Table 93: North American Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 94: North American Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 95: North American Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 96: North American Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 97: North American Market for Hematology Drugs, by Drug Type, Through 2029
Table 98: European Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 99: European Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 100: European Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 101: European Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 102: European Market for Hematology Drugs, by Drug Type, Through 2029
Table 103: Incidence of Blood-Related Cancers, by Country, 2022
Table 104: Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 105: Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 106: Asia-Pacific Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 107: Asia-Pacific Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 108: Asia-Pacific Market for Hematology Drugs, by Drug Type, Through 2029
Table 109: Asia-Pacific Incidence of Blood-Related Cancers, by Country, 2022
Table 110: RoW Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 111: RoW Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 112: RoW Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 113: RoW Market for Hematology Drugs, by Drug Type, Through 2029
Table 114: Global Market for In Vitro Diagnostics Quality Controls, by Test Type, Through 2029
Table 115: Global Market for In Vitro Diagnostics Quality Controls, by Test Type, Through 2029
Table 116: Global Market for Immunodiagnostics, by Region, Through 2029
Table 117: Global Market for Clinical Chemistry, by Region, Through 2029
Table 118: Global Market for Hematology, by Region, Through 2029
Table 119: Global Market for Molecular Diagnostics, by Region, Through 2029
Table 120: Global Market for Microbiology, by Region, Through 2029
Table 121: Global Market for Other Test Types, by Region, Through 2029
Table 122: Global Market for In Vitro Diagnostics Quality Controls, by Type of Manufacturer, Through 2029
Table 123: Global Market for Third-party Controls, by Region, Through 2029
Table 124: Global Market for ODM Controls, by Region, Through 2029
Table 125: Global Market for In Vitro Diagnostics Quality Controls, by Type of Product and Service, Through 2029
Table 126: Global Market for Quality Control Products, by Region, Through 2029
Table 127: Global Market for Serum/Plasma-Based Controls, by Region, Through 2029
Table 128: Global Market for Whole Blood-Based Controls, by Region, Through 2029
Table 129: Global Market for Urine-based Controls, by Region, Through 2029
Table 130: Global Market for Other Quality Control Products, by Region, Through 2029
Table 131: Global Market for Data Management Solutions, by Region, Through 2029
Table 132: Global Market for Quality Assurance Services, by Region, Through 2029
Table 133: Global Market for In Vitro Diagnostics Quality Controls, by End User, Through 2029
Table 134: Global Market for IVD Quality Controls in Diagnostic Laboratories, by Region, Through 2029
Table 135: Global Market for IVD Quality Controls in Hospitals and Clinics, by Region, Through 2029
Table 136: Global Market for IVD Quality Controls in Point-of-Care Centers, by Region, Through 2029
Table 137: Global Market for IVD Quality Controls in Research Institutions, by Region, Through 2029
Table 138: Global Market for Other End Users, by Region, Through 2029
Table 139: Global Market for In Vitro Diagnostics Quality Controls, by Region, Through 2029
Table 140: North American Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029
Table 141: European Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029
Table 142: Asia-Pacific Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029
Table 143: Rest of the World Market for In Vitro Diagnostics Quality Controls, by Country/Sub-Region, Through 2029
Table 144: Global Market for Point-of-Care Diagnostics, by Region, Through 2029
Table 145: POCT Alternatative Terms
Table 146: Commonly Used POC Devices
Table 147: Recent Tests Approved by the FDA as Waived Tests Under CLIA
Table 148: Estimated Number of People Living with HIV, 2010, 2021 and 2022
Table 149: Number of Hepatitis B Infections (All Ages) in 2022
Table 150: Global Incidences of STIs, 2020 and 2022
Table 151: Projected Number of Adults 50 Years and Older with =1 Chronic Condition in the United States, 2020-2050
Table 152: Number and Proportion of Persons Aged 65 Years and Over, by Development Group, 2023 and 2050
Table 153: Number of Persons Aged 65 Years and Over, by Region, 2019 and 2050
Table 154: Number of Deaths and the Age-Adjusted Death Rate for the 10 Leading Causes of Death in 2022: United States, 2021 and 2022
Table 155: Global Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 156: Global Market for Drug and Alcohol Screening, by Region, Through 2029
Table 157: Global Market for BGEM, by Region, Through 2029
Table 158: Global Market for Cardiac Markers, by Region, Through 2029
Table 159: Global Market for Cholesterol Testing/Monitoring, by Region, Through 2029
Table 160: Global Market for Glucose Testing and Monitoring, by Region, Through 2029
Table 161: Annual Estimated Deaths from HIV/AIDS, Diarrhea, Malaria, Respiratory Infections, and All Other Infectious Diseases in Major Countries, 1980 to 2021
Table 162: Global Market for Infectious Disease Testing, by Region, Through 2029
Table 163: Global Market for Pregnancy and Fertility Testing, by Region, Through 2029
Table 164: Global Market for Hemoglobin and Hemostasis, by Region, Through 2029
Table 165: Examples of Commercially Available POC Devices for Cancer Detection
Table 166: Global Market for Tumor Markers, by Region, Through 2029
Table 167: Some Currently Available Point-of-Care Tests for Proteins in Urine
Table 168: Global Market for Urinalysis/Urine Chemistry, by Region, Through 2029
Table 169: Global Market for Other Types of Point-of-Care Diagnostics Tests, by Region, Through 2029
Table 170: Global Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 171: Global Market for Hardware in Point-of-Care Diagnostics, by Region, Through 2029
Table 172: Global Market for Software in Point-of-Care Diagnostics, by Region, Through 2029
Table 173: Global Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 174: Global Market for Point-of-Care Diagnostics in Hospital and Critical Care End Uses, by Region, Through 2029
Table 175: Global Market for Point-of-Care Diagnostics in Home Care Settings, by Region, Through 2029
Table 176: Global Market for Point-of-Care Diagnostics, by Region, Through 2029
Table 177: North American Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 178: North American Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 179: North American Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 180: North American Market for Point-of-Care Diagnostics, by Country, Through 2029
Table 181: U.S. Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 182: U.S. Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 183: U.S. Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 184: Canadian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 185: Canadian Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 186: Canadian Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 187: Mexican Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 188: Mexican Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 189: Mexican Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 190: European Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 191: European Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 192: European Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 193: European Market for Point-of-Care Diagnostics, by Country, Through 2029
Table 194: Leading Causes of Disease Burden by DALYs (Level 3)
Table 195: German Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 196: German Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 197: German Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 198: U.K. Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 199: U.K. Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 200: U.K. Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 201: French Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 202: French Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 203: French Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 204: Italian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 205: Italian Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 206: Italian Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 207: Spanish Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 208: Spanish Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 209: Spanish Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 210: Rest of European Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 211: Rest of European Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 212: Rest of European Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 213: Asia-Pacific Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 214: Asia-Pacific Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 215: Asia-Pacific Market for Point-of-Care Diagnostics, by End User Through 2029
Table 216: Asia-Pacific Market for Point-of-Care Diagnostics, by Country, Through 2029
Table 217: Chinese Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 218: Chinese Market for Point-of-Care Diagnostics, by Product, Through 2029Chinese Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 219: Chinese Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 220: Japanese Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 221: Japanese Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 222: Japanese Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 223: Indian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 224: Indian Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 225: Indian Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 226: Australian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 227: Australian Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 228: Australian Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 229: South Korean Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 230: South Korean Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 231: South Korean Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 232: Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 233: Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 234: Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 235: Rest of the World Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 236: Rest of the World Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 237: Rest of the World Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 238: Global Market for Polymerase Chain Reaction for Point-of-Care Diagnostics, by Product Type, Through 2029
Table 239: Global HIV Infections, 2022
Table 240: People Living with HIV, by Region, 2022
Table 241: Global Incidence of All Cancers, by Region, 2022-2050
Table 242: Global Incidence of Leukemia, by Region, 2022-2050
Table 243: Global Incidence of Hodgkin Lymphoma, by Region, 2022-2050
Table 244: Global Incidence of Non-Hodgkin Lymphoma, by Region, 2022-2050
Table 245: Global Incidence of Multiple Myeloma, by Region, 2022-2050
Table 246: Global Market for PCR POC Diagnostics, Through 2029
Table 247: Global Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 248: Global Market for PCR POC Analyzers, by Analyte, Through 2029
Table 249: Global Market for Single Analyte PCR POC Analyzers, by Region, Through 2029
Table 250: Global Market for Multi-Analyte PCR POC Analyzers, by Region, Through 2029
Table 251: Global Market for PCR POC Consumables, by Analyte, Through 2029
Table 252: Global Market for Single Analyte PCR POC Consumables, by Region, Through 2029
Table 253: Global Market for Multi-Analyte PCR POC Consumables, by Region, Through 2029
Table 254: Global Market for PCR for POC Diagnostics, by Application, Through 2029
Table 255: Global Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 256: Global Market for PCR POC Diagnostics in Infectious Diseases, by Region, Through 2029
Table 257: North American Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 258: North American Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
Table 259: Latin American Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 260: Latin American Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
Table 261: European Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 262: European Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
Table 263: Asia-Pacific Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 264: Asia-Pacific Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
Table 265: RoW Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 266: Global Market for PCR POC Diagnostics in STIs, Through 2029
Table 267: Global Market for PCR POC Diagnostics in STIs, by Region, Through 2029
Table 268: North American Market for PCR POC Diagnostics in STIs, Through 2029
Table 269: North American Market for PCR POC Diagnostics in STIs, by Country, Through 2029
Table 270: Latin American Market for PCR POC Diagnostics in STIs, Through 2029
Table 271: Latin American Market for PCR POC Diagnostics in STIs, by Country, Through 2029
Table 272: European Market for PCR POC Diagnostics in STIs, Through 2029
Table 273: European Market for PCR POC Diagnostics in STIs, by Country, Through 2029
Table 274: Asia-Pacific Market for PCR POC Diagnostics in STIs, Through 2029
Table 275: Asia-Pacific Market for PCR POC Diagnostics in STIs, by Country, Through 2029
Table 276: RoW Market for PCR POC Diagnostics in STIs, Through 2029
Table 277: Global Market for PCR for POC Diagnostics, by Region, Through 2029
Table 278: North American Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 279: North American Market for PCR POC Diagnostics, by Country, Through 2029
Table 280: Latin American Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 281: Latin American Market for PCR POC Diagnostics, by Country, Through 2029
Table 282: European Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 283: European Market for PCR POC Diagnostics, by Country, Through 2029
Table 284: Asia-Pacific Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 285: Asia-Pacific Market for PCR POC Diagnostics, by Country, Through 2029
Table 286: RoW Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 287: Global Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 288: Rare Disease Prevalence Definitions
Table 289: Statistics for Rare Diseases
Table 290: Most Prevalent Rare Diseases
Table 291: Examples of Genomic Biomarkers
Table 292: Rare Disease Diagnostics Key Genetic Analysis Platforms
Table 293: Genome Coverage of PCR, Microarray and NGS Technology Platforms
Table 294: NGS vs. qPCR vs. Microarrays: A Detailed Comparison
Table 295: Multiple Paths to Market for Rare Disease Tests
Table 296: Bioinformatic Resources for Rare Disease Research and Genetic Information
Table 297: Impact of Large-Scale Initiatives on the Rare Disease Diagnostic Industry
Table 298: Key Rare Disease Initiatives
Table 299: Population Sequencing Projects
Table 300: Pathways for Accelerated Approval of Rare Disease Therapies, by Country/Region
Table 301: Genetic Modification Approaches for Rare Diseases
Table 302: Distinct Features of the Genetic Modification Approaches
Table 303: Comparison of Clinical Genomic Testing Methods for Analysis of Genomic Variants
Table 304: Driving Forces and Their Impact on Rare Disease Diagnostic Market Growth
Table 305: Rare Disease Diagnostics Artificial Intelligence Industry
Table 306: Global Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 307: NGS Applications in Rare Diseases
Table 308: Key Forces Driving Growth in Clinical NGS and Their Implications
Table 309: Main Ingredients for Polymerase Chain Reaction
Table 310: Polymerase Chain Reaction Process Steps
Table 311: Sanger Sequencing Summary
Table 312: Sanger Sequencing Improvements
Table 313: Molecular Genetic Testing Methods
Table 314: Cytogenetics Testing Methods
Table 315: Biochemical Genetics Methods
Table 316: Global Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
Table 317: Single-Gene Disorders
Table 318: Comparison of Techniques Employed to Study Rare Genetic Diseases
Table 319: Comparison of Genomic Methods for Rare Disease Diagnosis
Table 320: Global Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 321: Rare Cancer-Focused Initiatives and Consortia
Table 322: Selected Rare Cancer Prevalence, 2022
Table 323: Global Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 324: Preventive Genetic Screening Tests
Table 325: Global Market for Rare Disease Diagnostics, by Region, Through 2029
Table 326: NIH Funding, 2018-FY2025
Table 327: Key FDA Programs to Support Rare Disease Research
Table 328: North American Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 329: North American Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
Table 330: North American Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 331: North American Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 332: North American Market for Rare Disease Diagnostics, by Country, Through 2029
Table 333: U.S. Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 334: U.S. Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 335: Canadian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 336: Canadian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 337: Mexican Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 338: Mexican Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 339: Overview of Actions Taken by the EU to Address Challenges in the Field of Rare Diseases Diagnosis
Table 340: European Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 341: European Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
Table 342: European Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 343: European Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 344: European Market for Rare Disease Diagnostics, by Country, Through 2029
Table 345: German Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 346: German Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 347: U.K. Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 348: U.K. Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 349: French Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 350: French Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 351: Italian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 352: Italian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 353: Spanish Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 354: Spanish Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 355: Rest of European Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 356: Rest of European Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 357: Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 358: Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
Table 359: Asia-Pacific Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 360: Asia-Pacific Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 361: Asia-Pacific Market for Rare Disease Diagnostics, by Country, Through 2029
Table 362: Chinese Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 363: Chinese Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 364: Japanese Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 365: Japanese Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 366: Australian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 367: Australian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 368: South Korean Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 369: South Korean Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 370: Rest of Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 371: Rest of Asia-Pacific Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 372: RoW Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 373: RoW Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
Table 374: RoW Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 375: RoW Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Figure 1: Market Dynamics of AI in Clinical and Molecular Diagnostics
Figure 2: Global Market Shares of AI in Clinical and Molecular Diagnostics, by Type, 2023
Figure 3: Global Market Shares of AI in Molecular Diagnostics, by Application, 2023
Figure 4: Global Deaths from Cancer, 2015 and 2030
Figure 5: Global Market Shares of AI in Molecular Diagnostics, by Product Type, 2023
Figure 6: Global Market Shares of AI in Clinical Diagnostics, by Test, 2023
Figure 7: Global Market Shares of AI in Clinical Diagnostics, by Product, 2023
Figure 8: Global Market Shares of AI in Clinical and Molecular Diagnostics, by Component, 2023
Figure 9: Global Market Shares of AI in Clinical and Molecular Diagnostics, by Region, 2023
Figure 10: North American Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
Figure 11: European Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
Figure 12: Asia-Pacific Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
Figure 13: RoW Market Shares of AI in Clinical and Molecular Diagnostics, by Sub-Region, 2023
Figure 14: Timeline of FDA Guidance Release for Companion Diagnostics (CDx), as of 2023
Figure 15: Market Dynamics of Companion Diagnostics
Figure 16: Share of Global Cancer Incidence for Both Sexes, by Region, 2022
Figure 17: Companion Diagnostics: Growing Share in Total New Molecular Entities (NMEs), 2019-2022
Figure 18: Emerging Trends/Technologies in the Companion Diagnostics Market
Figure 19: Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, 2021-2029
Figure 20: Market Dynamics of Drugs and Diagnostics for Hematological Disorders
Figure 21: Incidence of Blood Cancer Types, by Region, 2022
Figure 22: Global Market Shares of Drugs and Diagnostics for Hematological Disorders, by Segment, 2023
Figure 23: Global Market Shares of Diagnostics for Hematological Disorders, by Product Type, 2023
Figure 24: Global Market Shares of Diagnostics for Hematological Disorders, by End User, 2023
Figure 25: Global Market Shares of Hematology Drugs, by Drug Type, 2023
Figure 26: North American Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 27: New Cases of Leukemia, Lymphoma and Myeloma in U.S., 2023
Figure 28: European Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 29: Asia-Pacific Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 30: Global Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
Figure 31: In Vitro Diagnostics (IVD) Quality Controls Global Market: Market Dynamics
Figure 32: Distribution of Elderly Population (Aged 65 and above), by Top Countries, 2022
Figure 33: Comparison Between Third-Party Controls and Original Equipment Manufacturer Controls
Figure 34: Global Market Shares of In Vitro Diagnostics Quality Controls, by Test Type 2023
Figure 35: Global Market Shares of In Vitro Diagnostics Quality Control, by Type of Manufacturer 2023
Figure 36: Global Market Shares of In Vitro Diagnostics Quality Controls, by Type of Product and Service, 2023
Figure 37: Global Market Shares of In Vitro Diagnostics Quality Controls, by Type of Quality Control Product, 2023
Figure 38: Global Market Shares of In Vitro Diagnostics Quality Controls, by End-user, 2023
Figure 39: Global Market Shares of In Vitro Diagnostics Quality Controls, by Region, 2023
Figure 40: North American Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
Figure 41: North American Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023
Figure 42: North American Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
Figure 43: North American Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
Figure 44: North American Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
Figure 45: North American Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023
Figure 46: European Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
Figure 47: European Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023
Figure 48: European Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
Figure 49: European Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
Figure 50: European Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
Figure 51: European Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023
Figure 52: Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
Figure 53: Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023
Figure 54: Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
Figure 55: Asia-Pacific Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
Figure 56: Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
Figure 57: Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023
Figure 58: Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
Figure 59: Rest of World Market Shares of In Vitro Diagnostic Quality Controls, by Type of Manufacturer, 2023
Figure 60: Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
Figure 61: Rest of World Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
Figure 62: Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
Figure 63: Rest of the World Market Shares of In Vitro Diagnostics Quality Controls, by Country/Sub-Region, 2023
Figure 64: Global Market Dynamics of Point-of-Care Diagnostics
Figure 65: Malaria-Endemic Countries, 2022
Figure 66: Top 10 Common Chronic Conditions in Adults 65+, U.S., 2024
Figure 67: Annual Investment in STI Research Needs of People in Low- and Middle-Income Countries, 2018-2022
Figure 68: Global Market Shares of Point-of-Care Diagnostics, by Test Type, 2023
Figure 69: Share of New Cancer Cases Globally, by Region, 2022
Figure 70: Share of Cancer Mortality Cases Globally, by Region, 2022
Figure 71: Global Market Shares of Point-of-Care Diagnostics, by Product, 2023
Figure 72: Global Market Shares of Point-of-Care Diagnostics, by End User, 2023
Figure 73: COVID-19 Diagnostic Possibilities, Sampling, and Turnaround Time
Figure 74: Global Market Shares of Point-of-Care Diagnostics, by Region, 2023
Figure 75: North American Market Shares in Point-of-Care Diagnostics, by Country, 2023
Figure 76: Limitations of Using POC Devices in India
Figure 77: Global Market Shares of Polymerase Chain Reaction for Point-of-Care Diagnostics, by Product Type, 2023
Figure 78: Polymerase Chain Reaction for Point of Care Diagnostics: Market Dynamics
Figure 79: Emerging Trends and Technologies in PCR for POC Diagnostics
Figure 80: Global Market Shares of Rare Disease Diagnostics, by Disease Class, 2023
Figure 81: Market Dynamics of Rare Disease Diagnostics
Figure 82: FDA Approval for Orphan Drugs, 2020-2023
Figure 83: Cost Per Genome, November 2017-May 2022
Figure 84: Phase-Out Plan of FDA’s Enforcement Discretion Approach
Figure 85: Global Market Shares of Rare Disease Diagnostics, by Analysis Platform, 2023
Figure 86: Global Market Shares of Rare Disease Diagnostics, by Analysis Target, 2023
Figure 87: Global Market Shares of Rare Disease Diagnostics, by Disease Class, 2023
Figure 88: Global Market Shares of Rare Disease Diagnostics, by Test Purpose, 2023
Figure 89: Global Market for Rare Disease Diagnostics, by Region, 2021-2029
Figure 90: Global Market Shares of Rare Disease Diagnostics, by Region, 2023
Figure 91: NIH Funding for Rare Diseases, 2018-2025E
Figure 92: North American Market Shares of Rare Disease Diagnostics, by Country, 2023
Figure 93: European Market Shares of Rare Disease Diagnostics, by Country, 2023
Figure 94: Asia-Pacific Market Shares of Rare Disease Diagnostics, by Country, 2023